Pilot study of tandem high-dose chemotherapy and autologous stem cell transplantation with a novel combination of regimens in patients with poor risk lymphoma

Bone Marrow Transplantation

Volumn 36, Issue 6, 2005, Pages 491-497

  Papadopoulos, K P ^a   Noguera Irizarry, W ^b   Wiebe, L ^b   Hesdorffer, C S ^b   Garvin, J ^b   Nichols, G L ^b   Vahdat, L H ^c   Lo, K M S ^d   Skerrett, D ^b   Bernstein, D ^b   Sharpe, E ^b   Savage, D G ^b,e  

^a CTRC Institute for Drug Development   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d Bennett Cancer Center   (United States)

^e Division of Medical Oncology   (United States)

Author keywords

Autologous; Lymphoma; Tandem transplantation

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; CARBOPLATIN; DOXORUBICIN; ETOPOFOS; MELPHALAN; MITOXANTRONE; THIOTEPA;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG MEGADOSE; DRUG TOLERABILITY; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HODGKIN DISEASE; HUMAN; INFECTION; LIVER DYSFUNCTION; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; PARENTERAL NUTRITION; PILOT STUDY; PRIORITY JOURNAL; SINUS TACHYCARDIA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA; MALE; MAXIMUM TOLERATED DOSE; MELPHALAN; MIDDLE AGED; MITOXANTRONE; PILOT PROJECTS; RISK; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 31044450886     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705103     Document Type: Article

References (22)

1. Hahn T, Wolff SN, Czuczman M et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: An evidence-based review. Biol Blood Marrow Transplant 2001; 7: 308-331.
2. Vitolo U, Cortellazzo S, Liberati AM et al. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma. J Clin Oncol 1997; 15: 491-498.
3. Stoppa AM, Bouabdallah R, Chabannon C et al. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 1722-1729.
4. Santini G, Coser P, Congiu AM et al. VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: A study by the non-Hodgkin's Lymphoma Co-operative Study Group. Haematologica 2000; 85: 160-166.
5. Cortelazzo S, Rambaldi A, Rossi A et al. Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma. Br J Haematol 2001; 114: 333-341.
6. Gryn J, Johnson E, Goldman N et al. The treatment of relapsed or refractory intermediate grade non-Hodgkin's lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon. Bone Marrow Transplant 1997; 19: 221-226.
7. Fitoussi O, Simon D, Brice P et al. Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkins's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant 1999; 24: 747-755.
8. Philip T, Bouabdallah R, Brice P. Phase II study testing a double intensification in aggressive non-Hodgkin's lymphoma relapsing less than one year after initial treatment (PARMA2 study). Bone Marrow Transplant 2000; 25: 5180 (Abstract P5559).
9. Ballestrero A, Clavio M, Ferrando F et al. High-dose chemotherapy with tandem autologous transplantation as part of the initial therapy for aggressive non-Hodgkin's lymphoma. Int J Oncol 2000; 17: 1007-1013.
10. Brice P, Divine M, Simon D et al. Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). SFGM/GELA Study Group. Ann Oncol 1999; 10: 1485-1488.
11. Le Gouill S, Moreau P, Morineau N et al. Tandem high-dose therapy followed by autologous stem-cell transplantation for refractory or relapsed high grade non-Hodgkin's lymphoma with poor prognosis factors: a prospective pilot study. Haematologica 2002; 87: 333-334.
12. Haioun C, Mounier N, Quesnel B et al. Tandem autotransplant as first-line consolidative treatment in poor-risk aggressive lymphoma: A pilot study of 36 patients. Ann Oncol 2001; 12: 1749-1755.
13. Barlogie B, Jagannath S, Vesole DH et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple mycloma. Blood 1997; 89: 789-793.
14. Attal M, Harousseau JL, Facon T et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Eng J Med 2003; 349: 2495-2502.
15. Corradini P, Astolfi M, Cherasco C et al. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood 1997; 89: 724-731.
16. Vahdat LT, Balmaceda C, Papadopoulos K et al. Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. Bone Marrow Transplant 2002; 30: 149-155.
17. Papadopoulos KP, Garvin JH, Fetell M et al. High-dose thiotepa and etoposide-based regimens with autologous hematopoietic support for high-risk or recurrent CNS tumors in children and adults. Bone Marrow Transplant 1998; 22: 661-667.
18. Hainsworth JD, Utley SM, Greco FA. Phase I study of high dose etoposide phosphatase with filgrastim (G-CSF) in the treatment of advanced refractory malignancies. Invest New Drugs 1997; 15: 325-329.
19. Tarella C, Zallio F, Caracciolo D et al. High-dose mitoxantrone + elphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: High tolerability with reversible cardiotoxicity. Leukemia 2001; 15: 256-263.
20. Papadopoulos KP, Noguera-Irizarry W, Hesdorffer CS. Tandem transplantation in lymphoma. Bone Marrow Transplant 2001; 28: 529-535.
21. Malek SN, Flinn IW. Incorporating monoclonal antibodies in blood and marrow transplantation. Semin Oncology 2003; 30: 520-530.
22. Horwitz SM, Negrin RS, Blume KG et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004; 103: 777-783.